Kuk Young G&M Co., Ltd. (KOSDAQ:006050)
South Korea · Delayed Price · Currency is KRW 1,303.00
+8.00 (0.62%)
Last updated: Aug 6, 2025
Ligand Pharmaceuticals Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Operating Revenue | 71,048 | 75,411 | 76,641 | 63,599 | 55,030 | 64,386 | Upgrade |
Other Revenue | - | -0 | -0 | -0 | 0 | -0 | Upgrade |
| 71,048 | 75,411 | 76,641 | 63,599 | 55,030 | 64,386 | Upgrade | |
Revenue Growth (YoY) | -7.70% | -1.60% | 20.51% | 15.57% | -14.53% | -11.82% | Upgrade |
Cost of Revenue | 65,166 | 70,013 | 72,268 | 58,435 | 59,422 | 64,158 | Upgrade |
Gross Profit | 5,882 | 5,399 | 4,373 | 5,165 | -4,392 | 227.82 | Upgrade |
Selling, General & Admin | 3,227 | 3,649 | 3,151 | 2,862 | 2,203 | 2,179 | Upgrade |
Operating Expenses | 4,019 | 4,496 | 3,430 | 3,043 | 2,348 | 2,289 | Upgrade |
Operating Income | 1,862 | 902.78 | 942.17 | 2,121 | -6,740 | -2,061 | Upgrade |
Interest Expense | -260.2 | -269.92 | -319.16 | -243.26 | -144.29 | -111.11 | Upgrade |
Interest & Investment Income | 356.99 | 529.64 | 204.99 | 131.95 | 53.47 | 75.62 | Upgrade |
Currency Exchange Gain (Loss) | 134.76 | 171.08 | 69.3 | 133.76 | 117.22 | -67.95 | Upgrade |
Other Non Operating Income (Expenses) | 561.37 | 572.01 | 375.86 | 263.96 | 333.12 | 205.49 | Upgrade |
EBT Excluding Unusual Items | 2,655 | 1,906 | 1,273 | 2,408 | -6,380 | -1,959 | Upgrade |
Gain (Loss) on Sale of Investments | 246.08 | 19.06 | 27.31 | -7.37 | 24.79 | 14.66 | Upgrade |
Gain (Loss) on Sale of Assets | - | 3.27 | 502.95 | 14.45 | 10.45 | 17.91 | Upgrade |
Asset Writedown | 260.96 | 260.3 | - | - | - | - | Upgrade |
Pretax Income | 3,162 | 2,188 | 1,803 | 2,415 | -6,345 | -1,927 | Upgrade |
Income Tax Expense | -300.1 | -391.89 | 1,025 | 557.18 | -1,485 | -621.38 | Upgrade |
Net Income | 3,463 | 2,580 | 778.35 | 1,858 | -4,860 | -1,305 | Upgrade |
Net Income to Common | 3,463 | 2,580 | 778.35 | 1,858 | -4,860 | -1,305 | Upgrade |
Net Income Growth | 487.63% | 231.48% | -58.10% | - | - | - | Upgrade |
Shares Outstanding (Basic) | 34 | 34 | 34 | 34 | 34 | 34 | Upgrade |
Shares Outstanding (Diluted) | 34 | 34 | 34 | 34 | 34 | 34 | Upgrade |
EPS (Basic) | 102.15 | 76.12 | 22.96 | 54.80 | -143.40 | -38.51 | Upgrade |
EPS (Diluted) | 102.15 | 76.12 | 22.96 | 54.80 | -143.40 | -38.51 | Upgrade |
EPS Growth | 487.63% | 231.48% | -58.10% | - | - | - | Upgrade |
Free Cash Flow | 5,338 | 6,101 | 4,103 | -4,579 | -1,853 | 3,822 | Upgrade |
Free Cash Flow Per Share | 157.49 | 179.99 | 121.03 | -135.10 | -54.67 | 112.76 | Upgrade |
Gross Margin | 8.28% | 7.16% | 5.71% | 8.12% | -7.98% | 0.35% | Upgrade |
Operating Margin | 2.62% | 1.20% | 1.23% | 3.33% | -12.25% | -3.20% | Upgrade |
Profit Margin | 4.87% | 3.42% | 1.02% | 2.92% | -8.83% | -2.03% | Upgrade |
Free Cash Flow Margin | 7.51% | 8.09% | 5.35% | -7.20% | -3.37% | 5.94% | Upgrade |
EBITDA | 3,278 | 2,331 | 2,301 | 3,454 | -5,089 | -438.37 | Upgrade |
EBITDA Margin | 4.61% | 3.09% | 3.00% | 5.43% | -9.25% | -0.68% | Upgrade |
D&A For EBITDA | 1,415 | 1,428 | 1,359 | 1,333 | 1,651 | 1,623 | Upgrade |
EBIT | 1,862 | 902.78 | 942.17 | 2,121 | -6,740 | -2,061 | Upgrade |
EBIT Margin | 2.62% | 1.20% | 1.23% | 3.33% | -12.25% | -3.20% | Upgrade |
Effective Tax Rate | - | - | 56.84% | 23.07% | - | - | Upgrade |
Updated Mar 1, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.